Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats

Japanese Journal of Pharmacology

Volumn 81, Issue 2, 1999, Pages 216-222

  Kosasa, Takashi ^a   Kuriya, Yuka ^a   Yamanishi, Yoshiharu ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Acetylcholine; Acetylcholinesterase inhibitor; Cerebral cortex; Donepezil hydrochloride (E2020); Microdialysis

Indexed keywords

ACETYLCHOLINE; DONEPEZIL; RIVASTIGMINE; TACRINE; ZANEPEZIL;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG SELECTIVITY; EXTRACELLULAR FLUID; FASCICULATION; MALE; MICRODIALYSIS; NEUROMUSCULAR TRANSMISSION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

ANIMALS; BENZAZEPINES; CARBAMATES; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCHEMISTRY; EXTRACELLULAR SPACE; INDANS; MALE; MICRODIALYSIS; NOOTROPIC AGENTS; PERIPHERAL NERVOUS SYSTEM; PHENYLCARBAMATES; PIPERIDINES; RATS; RATS, WISTAR; TACRINE;

EID: 0032754559     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.81.216     Document Type: Article

References (32)

1. Whitehouse PJ, Price DR, Struble RG, Clark AW, Coyle JT and Delong MR: Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237-1239 (1982)
2. Bowen DM, Smith CB, White P and Davison AN: Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99, 459-496 (1976)
3. Davis P and Maloney AJF: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2, 1403 (1976)
4. Perry EK, Gibson PH, Blessed G, Perry RH and Tomlinson BE: Neurotransmitter enzyme abnormalities in senile dementia: Choline acetyltransferase and glutamic acid decarboxylase in necropsy brain tissue. J Neurol Sci 34, 247-265 (1977)
5. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH and Perry RH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2, 1456-1459 (1978)
6. Drachman DA: Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27, 783-790 (1977)
7. Summers WK, Majovski LV, Marsh GM, Tachiki K and Kling A: Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Eng J Med 315, 1241-1245 (1986)
8. Beermann B: Side effects of long acting cholinesterase inhibitor. Acta Neurol Scand 149, 53-54 (1993)
9. Sugimoto H, Iimura Y, Yamanishi Y and Yamatsu K: Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl] piperidine hydrochloride and related compounds. J Med Chem 38, 4821-4829 (1995)
10. Rogers SL, Friedhoff LT and the Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 7, 293-303 (1996)
11. Rogers SL, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group: Donepezil improves cognitive and global function in Alzheimer's disease: A 15-week double-blind, placebo-controlled study. Arch Intern Med 158, 1021-1031 (1998)
12. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50, 136-145 (1998)
13. Rogers SL and Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicenter open label extension study. Eur Neuropsychopharmacol 8, 67-75 (1998)
14. Rogers SL, Yamanishi Y and Yamatsu K: E2020: the pharmacology of a piperidine cholinesterase inhibitor. In Cholinergic Basis for Alzheimer Therapy, Edited by Becker R and Giacobini E, pp 314-320, Birkhäuser, Boston (1991)
15. Yamanishi Y, Araki S, Kosasa T, Ogura H and Yamatsu K: Neurochemical studies of E2020, a novel centrally acting acetylcholinesterase inhibitor. Soc Neurosci Abstr 14, 59 (1988)
16. Ogura H, Kosasa T, Araki S, Yamanishi Y, and Yamatsu K: Behavioral study of E2020, a novel centrally acting acetylcholinesterase inhibitor. Soc Neurosci Abstr 14, 60 (1988)
17. Weinstock M, Razin M, Chorev M and Enz A: Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm 43, 219-225 (1994)
18. Hirai K, Kato K, Nakayama T, Hayako H, Ishihara Y, Goto G and Miyamoto M: Neurochemical effects of 3-[1-(phenyl-methyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- 1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, in rats. J Pharmacol Exp Ther 280, 1261-1269 (1997)
19. Taylor P: Anticholinesterase agents. In Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th ed, Edited by Hardman JG, Limbird LE, Molinoff PB, Ruddon RW and Gilman AG, pp 161-176, McGraw-Hill, New York (1996)
20. Sprouse JS and Baker T: Measurement of fasciculation as motor nerve ending discharges in the rat: a dose related effect of neostigmine. Proc Soc Exp Biol Med 178, 304-308 (1985)
21. Maysinger D, Herrera-Marschitz M, Carlsson A, Garofalo L, Cuello AC and Ungerstedt U: Striatal and cortical acetylcholine release in vivo in rats with unilateral decortication: effects of treatment with monosialoganglioside GM1. Brain Res 461, 355-360 (1988)
22. Paxinos G and Watson C: The Rat Brain in Stereotaxic Coordinates, 2nd edn, Academic Press, Sydney (1986)
23. Messamore E, Ogane N and Giacobini E: Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum. Neuropharmacology 32, 291-296 (1993)
24. Kawashima K, Sato A, Yoshizawa M, Fujii T, Fujimoto K and Suzuki T: Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 350, 523-528 (1994)
25. Giacobini E, Zhu X-D, Williams E and Sherman KA: The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 35, 205-211 (1996)
26. Yamanishi Y, Ogura H, Kosasa T, Uchikoshi K, Sawa Y and Yamatsu K: Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase in aged rats. Eur J Pharmacol 183, Suppl, 1935 (1990)
27. Whitehouse PJ: Donepezil. Drugs of Today 34, 321-326 (1998)
28. Barner EL and Gray SL: Donepezil use in Alzheimer disease. Ann Pharmacother 32, 70-77 (1998)
29. Tune LE and Sunderland T: New cholinergic therapies: treatment tools for the psychiatrist. J Clin Psychiatry 59, Suppl 13, 31-35 (1998)
30. Giacobini E: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int 32, 413-419 (1998)
31. De Bore P, Westerink BHC and Horn AS: The effect of acetylcholinesterase inhibition on the release of acetylcholine from the striatum in vivo: interaction with autoreceptor responses. Neurosci Lett 116, 357-360 (1990)
32. Kawashima K, Hayakawa T, Kashima Y, Suzuki T, Fujimoto K and Oohata H: Determination of acetylcholine release in the striatum of anesthetized rats using in vivo microdialysis and radioimmunoassay. J Neurochem 57, 882-887 (1991)